BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 12829671)

  • 21. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
    Rudà R; Bosa C; Magistrello M; Franchino F; Pellerino A; Fiano V; Trevisan M; Cassoni P; Soffietti R
    Neuro Oncol; 2016 Feb; 18(2):261-8. PubMed ID: 26323606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
    van den Bent MJ; Kros JM; Heimans JJ; Pronk LC; van Groeningen CJ; Krouwer HG; Taphoorn MJ; Zonnenberg BA; Tijssen CC; Twijnstra A; Punt CJ; Boogerd W
    Neurology; 1998 Oct; 51(4):1140-5. PubMed ID: 9781544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
    Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
    J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
    Chamberlain MC
    Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
    Yung WK; Prados MD; Yaya-Tur R; Rosenfeld SS; Brada M; Friedman HS; Albright R; Olson J; Chang SM; O'Neill AM; Friedman AH; Bruner J; Yue N; Dugan M; Zaknoen S; Levin VA
    J Clin Oncol; 1999 Sep; 17(9):2762-71. PubMed ID: 10561351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage temozolomide for prior temozolomide responders.
    Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
    Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
    Hoang-Xuan K; Capelle L; Kujas M; Taillibert S; Duffau H; Lejeune J; Polivka M; Crinière E; Marie Y; Mokhtari K; Carpentier AF; Laigle F; Simon JM; Cornu P; Broët P; Sanson M; Delattre JY
    J Clin Oncol; 2004 Aug; 22(15):3133-8. PubMed ID: 15284265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
    Chan DT; Poon WS; Chan YL; Ng HK
    Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of temozolomide treatment in patients with high-grade glioma.
    Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
    Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
    Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
    Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
    Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
    J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C; Shonka N; Smith L; Liu D; De Groot J
    Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
    Cairncross G; Macdonald D; Ludwin S; Lee D; Cascino T; Buckner J; Fulton D; Dropcho E; Stewart D; Schold C
    J Clin Oncol; 1994 Oct; 12(10):2013-21. PubMed ID: 7931469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
    Chamberlain MC; Glantz MJ
    J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
    Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
    Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.